[go: up one dir, main page]

WO1997040165B1 - Nouveaux produits de construction d'adn de cytomegalovirus humain, et leurs utilisations - Google Patents

Nouveaux produits de construction d'adn de cytomegalovirus humain, et leurs utilisations

Info

Publication number
WO1997040165B1
WO1997040165B1 PCT/US1997/006866 US9706866W WO9740165B1 WO 1997040165 B1 WO1997040165 B1 WO 1997040165B1 US 9706866 W US9706866 W US 9706866W WO 9740165 B1 WO9740165 B1 WO 9740165B1
Authority
WO
WIPO (PCT)
Prior art keywords
immunogenic composition
pδrc
group
hcmv
human cytomegalovirus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1997/006866
Other languages
English (en)
Other versions
WO1997040165A1 (fr
WO1997040165A9 (fr
Filing date
Publication date
Application filed filed Critical
Priority to EP97922429A priority Critical patent/EP0914441A2/fr
Priority to AU28098/97A priority patent/AU2809897A/en
Priority to US09/171,699 priority patent/US6448389B1/en
Publication of WO1997040165A1 publication Critical patent/WO1997040165A1/fr
Publication of WO1997040165B1 publication Critical patent/WO1997040165B1/fr
Publication of WO1997040165A9 publication Critical patent/WO1997040165A9/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Abstract

L'invention concerne des molécules d'ADN nouvelles servant à exprimer in vitro et in vivo le complexe gB du cytomégalovirus humain et des dérivés du complexe gB dont la transmembrane a été supprimée, tels que les protéines pp65, pp150 et IE-exon-4. Ces molécules sont de préférence des plasmides. L'invention concerne également des procédés d'utilisation de ces molécules d'ADN de façon à induire des réponses immunitaires en réaction au cytomégalovirus humain, et l'utilisation d'un plasmide de la présente invention, qui sert à amorcer des réponses immunitaires lors de l'administration de vaccins contre le cytomégalovirus humain.
PCT/US1997/006866 1996-04-23 1997-04-22 Nouveaux produits de construction d'adn de cytomegalovirus humain, et leurs utilisations Ceased WO1997040165A1 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP97922429A EP0914441A2 (fr) 1996-04-23 1997-04-22 Nouveaux produits de construction d'adn de cytomegalovirus humain, et leurs utilisations
AU28098/97A AU2809897A (en) 1996-04-23 1997-04-22 Novel human cytomegalovirus dna constructs and uses therefor
US09/171,699 US6448389B1 (en) 1996-04-23 1997-04-22 Human cytomegalovirus DNA constructs and uses therefor

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1571796P 1996-04-23 1996-04-23
US60/015,717 1996-04-23

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US09/171,699 A-371-Of-International US6448389B1 (en) 1996-04-23 1997-04-22 Human cytomegalovirus DNA constructs and uses therefor
US10/223,538 Division US20030120060A1 (en) 1996-04-23 2002-08-19 Human cytomegalovirus DNA constructs and uses therefor

Publications (3)

Publication Number Publication Date
WO1997040165A1 WO1997040165A1 (fr) 1997-10-30
WO1997040165B1 true WO1997040165B1 (fr) 1998-01-08
WO1997040165A9 WO1997040165A9 (fr) 1998-02-12

Family

ID=21773167

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1997/006866 Ceased WO1997040165A1 (fr) 1996-04-23 1997-04-22 Nouveaux produits de construction d'adn de cytomegalovirus humain, et leurs utilisations

Country Status (4)

Country Link
US (2) US6448389B1 (fr)
EP (1) EP0914441A2 (fr)
AU (1) AU2809897A (fr)
WO (1) WO1997040165A1 (fr)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0914441A2 (fr) 1996-04-23 1999-05-12 The Wistar Institute Of Anatomy And Biology Nouveaux produits de construction d'adn de cytomegalovirus humain, et leurs utilisations
EP0964686A4 (fr) 1996-08-14 2000-10-18 Wistar Inst Procedes et compositions pour empecher ou pour retarder le developpement de lesions atherosclereuses
US6562345B1 (en) * 1996-11-12 2003-05-13 City Of Hope Immuno-reactive peptide CTL epitopes of human cytomegalovirus
WO2000062817A2 (fr) * 1999-04-15 2000-10-26 Board Of Regents, The University Of Texas System Vaccins inductibles
EP1612217A3 (fr) * 2000-03-27 2006-01-18 City of Hope Epitopes ctl peptidiques immunoréactifs du cytomégalovirus
US6783939B2 (en) * 2000-07-07 2004-08-31 Alphavax, Inc. Alphavirus vectors and virosomes with modified HIV genes for use in vaccines
AU2001271998A1 (en) * 2000-07-13 2002-01-30 The Johns Hopkins University School Of Medicine Detection and treatment of polycystic kidney disease
WO2002020811A2 (fr) * 2000-09-09 2002-03-14 Basf Plant Science Gmbh Systeme inductible tet modifie permettant la regulation de l'expression genique dans des plantes
WO2002034769A2 (fr) 2000-10-20 2002-05-02 City Of Hope Epitopes ctl peptidiques immunoreactifs du cytomegalovirus pp150
DE60233061D1 (de) * 2001-09-06 2009-09-03 Alphavax Inc Alphavirus replikon-vektorsysteme
CA2756797C (fr) * 2002-12-23 2015-05-05 Vical Incorporated Vaccins a base de polynucleotides a codon optimise diriges contre l'infection par le cytomegalovirus humain
PL378110A1 (pl) * 2003-02-14 2006-03-06 Biogen Idec Ma Inc. Kaseta ekspresyjna i wektor do przejściowej albo stabilnej ekspresji egzogennych cząsteczek
WO2004076645A2 (fr) * 2003-02-27 2004-09-10 University Of Massachusetts Compositions et methodes de traitement du cytomegalovirus
KR101454842B1 (ko) * 2003-03-20 2014-11-04 알파벡스, 인크. 개선된 알파바이러스 레플리콘 및 헬퍼 구축물
AU2004257214B2 (en) * 2003-07-11 2010-04-22 Alphavax, Inc. Alphavirus-based cytomegalovirus vaccines
EP1799255A4 (fr) * 2004-06-25 2008-10-01 Medimmune Vaccines Inc Cytomegalovirus humain de recombinaison et vaccins contenant des antigenes heterologues
AU2008266807B2 (en) * 2007-06-21 2012-08-16 Alphavax, Inc. Promoterless cassettes for expression of alphavirus structural proteins
EP3156069B8 (fr) 2008-06-20 2020-10-21 Duke University Compositions, procédés et kits permettant de provoquer une réponse immunitaire
US8812387B1 (en) 2013-03-14 2014-08-19 Csidentity Corporation System and method for identifying related credit inquiries
US10023626B2 (en) 2013-09-30 2018-07-17 Modernatx, Inc. Polynucleotides encoding immune modulating polypeptides
JP6679484B2 (ja) * 2013-12-11 2020-04-15 ザ ヘンリー エム． ジャクソン ファウンデーション フォー ザ アドヴァンスメント オブ ミリタリー メディシン インコーポレイテッド ヒトヘルペスウイルス三量体糖タンパク質Ｂ、三量体ｇＢを含むタンパク質複合体、及びワクチンとしてのそれらの使用
CA3002922A1 (fr) 2015-10-22 2017-04-27 Modernatx, Inc. Vaccin contre le cytomegalovirus humain
RU2616245C2 (ru) * 2015-12-29 2017-04-13 Сейфаддин Гашим Оглы Марданлы Композиция для профилактики заболеваний, вызываемых цитомегаловирусной инфекцией
US10611800B2 (en) 2016-03-11 2020-04-07 Pfizer Inc. Human cytomegalovirus gB polypeptide
AU2017345766A1 (en) 2016-10-21 2019-05-16 Modernatx, Inc. Human cytomegalovirus vaccine
US11629172B2 (en) 2018-12-21 2023-04-18 Pfizer Inc. Human cytomegalovirus gB polypeptide
US11857622B2 (en) 2020-06-21 2024-01-02 Pfizer Inc. Human cytomegalovirus GB polypeptide
US11406703B2 (en) 2020-08-25 2022-08-09 Modernatx, Inc. Human cytomegalovirus vaccine

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3959466A (en) 1974-04-15 1976-05-25 The Wistar Institute Highly attenuated cytomegalovirus vaccine and production thereof
ZA858044B (en) 1984-11-01 1987-05-27 American Home Prod Oral vaccines
US4689225A (en) 1984-11-02 1987-08-25 Institut Merieux Vaccine for cytomegalovirus
CA1335429C (fr) 1986-03-07 1995-05-02 Geoffrey L. Smith Procedes de fabrication de glycoproteines hcmv, les anticorps et les vaccins diriges contre ces glycoproteines hcmv, et leurs vecteurs recombinants
ATE82985T1 (de) * 1986-06-12 1992-12-15 Behringwerke Ag Strukturelles phosphoprotein (pp 150) des menschlichen cytomegalovirus, seine herstellung und verwendung.
DE3619720A1 (de) 1986-06-12 1987-12-17 Behringwerke Ag Hauptglykoprotein des menschlichen cytomegalovirus, seine herstellung und verwendung
DE3619902A1 (de) 1986-06-13 1988-03-03 Biotechnolog Forschung Gmbh Cmv-dna-strukturen, expressionsvektor dafuer, cmv-proteinstrukturen und deren verwendung
ZA878031B (en) 1986-11-04 1988-04-28 Scripps Clinic And Research Foundation Nucleic acid probes for the detection of latent human cytomegalovirus in blood products
US5153311A (en) 1986-11-24 1992-10-06 The Children's Hospital, Incorporated Immunogenic glycoproteins of human cytomegalovirus gCII
US5124440A (en) 1986-11-24 1992-06-23 The Childrens Hospital, Inc. Antibody and T cell recognition sites on glycoproteins comprising the GCI complex of human cytomegalovirus
EP0277773A1 (fr) 1987-01-30 1988-08-10 The Board Of Trustees Of The Leland Stanford Junior University Cytomégalovirus hybride et vaccin
JP2607712B2 (ja) * 1988-01-29 1997-05-07 カイロン コーポレイション 組換えｃｍｖ中和タンパク
AU3849989A (en) 1988-07-01 1990-01-23 Children's Hospital Incorporated, The Antibody recognition of fragments from cytomegalovirus
WO1990006771A1 (fr) 1988-12-12 1990-06-28 The Children's Hospital, Incorporated Fragments proteolytiques obtenus a partir du complexe i de glycoproteines de cytomegalovirus humain
US5591439A (en) 1989-03-24 1997-01-07 The Wistar Institute Of Anatomy And Biology Recombinant cytomegalovirus vaccine
EP0389286B1 (fr) 1989-03-24 1996-07-10 The Wistar Institute Of Anatomy And Biology Vaccin recombinant contre le virus cytomégalo
US5552143A (en) 1989-03-24 1996-09-03 The Wistar Institute Of Anatomy & Biology Recombinant cytomegalovirus vaccine
WO1991002004A1 (fr) 1989-08-07 1991-02-21 Children's Biomedical Research Center GLYCOPROTEINES IMMUNOGENIQUES DU CYTOMEGALOVIRUS HUMAIN gCII
AU7906691A (en) 1990-05-23 1991-12-10 United States of America, as represented by the Secretary, U.S. Department of Commerce, The Adeno-associated virus (aav)-based eucaryotic vectors
GB9014652D0 (en) 1990-07-02 1990-08-22 Wellcome Found Antigen
JPH06501845A (ja) 1990-08-02 1994-03-03 カイロン　コーポレイション バキュロウイルス―昆虫細胞発現システムを用いたヒトｃｍｖ糖タンパク質―ｈの発現
FR2688514A1 (fr) 1992-03-16 1993-09-17 Centre Nat Rech Scient Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant.
WO1994017810A1 (fr) 1993-02-12 1994-08-18 The Wistar Institute Of Anatomy And Biology Vaccin recombine contre le cytomegalovirus
WO1994023744A1 (fr) 1993-04-16 1994-10-27 The Wistar Institute Of Anatomy And Biology Vaccin contenant un cytomegalovirus de recombinaison
IT1266740B1 (it) 1994-07-01 1997-01-14 Maria Paola Landini Materiale proteico ricombinante legante anticorpi contro il citomegalovirus umano, reagenti diagnostici derivati da tale
EP0914441A2 (fr) 1996-04-23 1999-05-12 The Wistar Institute Of Anatomy And Biology Nouveaux produits de construction d'adn de cytomegalovirus humain, et leurs utilisations

Similar Documents

Publication Publication Date Title
WO1997040165B1 (fr) Nouveaux produits de construction d'adn de cytomegalovirus humain, et leurs utilisations
Prehaud et al. Immunogenic and protective properties of rabies virus glycoprotein expressed by baculovirus vectors
Osterrieder et al. Protection against EHV-1 challenge infection in the murine model after vaccination with various formulations of recombinant glycoprotein gp14 (gB)
EP0139417B1 (fr) Vaccins à base de protéines liées à des membranes et procédé pour leur préparation
Yoo et al. The S2 subunit of the spike glycoprotein of bovine coronavirus mediates membrane fusion in insect cells
CA2228221A1 (fr) Produits de recombinaison de polyproteine de papillomavirus
Konishi et al. A vipox virus-vectored Japanese encephalitis virus vaccines: use as vaccine candidates in combination with purified subunit immunogens
Anderson et al. Definition of a human herpesvirus-6 betaherpesvirus-specific domain in glycoprotein gH that governs interaction with glycoprotein gL: substitution of human cytomegalovirus glycoproteins permits group-specific complex formation
CA2275340A1 (fr) Proteine de fusion comportant tout ou partie de la proteine pp65 de cmv humain, utile notamment dans la preparation d'un vaccin
AU3739999A (en) Introduction of naked dna or rna encoding non-human vertebrate peptide hormones or cytokines into a non-human vertebrate
EP0538341B1 (fr) Vaccin a base de glycoproteine de vhe-4 (virus d'herpes equin-4)
ALLEN et al. Role of coexpression of IL-2 and herpes simplex virus proteins in recombinant vaccinia virus vectors on levels of induced immunity
EP0117657A1 (fr) Polypeptides immunogènes contre la rage et vaccin utilisant ces peptides, séquences d'ADN, vecteurs d'expression, cellules recombinantes, cultures et procédés pour leur production
Meindl et al. The equine herpesvirus 1 Us2 homolog encodes a nonessential membrane-associated virion component
DE69534162T2 (de) Fusion-glykoprotein von hcmv und hsv
CN100415895C (zh) gp350/220的非剪接变异体
JPH06220099A (ja) 可溶性ｌｄｌリセプター
WO1998012333A1 (fr) Peptides immunogenes des virus de la fievre aphteuse
JP2852395B2 (ja) ネコ白血病ウイルスワクチン
Frenchick et al. Biochemical and immunological characterization of a novel peptide carrier system using rotavirus VP6 particles
WO1997003187A3 (fr) Genes du virus de la maladie de marek et leur utilisation dans des vaccins qui protegent contre la maladie de marek
CN102787119B (zh) 治疗和/或预防病毒感染的产品及方法
Osterrieder et al. Deletion of gene 52 encoding glycoprotein M of equine herpesvirus type 1 strain RacH results in increased immunogenicity
CA2047585A1 (fr) Vecteur viral constitue a partir d'un herpesvirus qui exprime un epitope de la fievre aphteuse a la surface des cellules infectees et des particules virales, et vaccin contre la fievre aphteuse contenant ce vecteur
Chikateru et al. Expression of herpes simplex virus glycoprotein B gene in yeast